Navigation Links
Jack Davis, Diagnostics Industry Executive, Joins the HistoRx Board of Directors
Date:12/15/2010

BRANFORD, Conn., Dec. 15, 2010 /PRNewswire/ -- HistoRx announces that Jack Davis has accepted its invitation to join the Board of Directors.  As the former President and CEO of both a diagnostic product company and a laboratory testing company, he is an acknowledged diagnostic industry expert.

Mr. Davis was Co-founder, President, CEO and eventually Chairman of the Board at Dianon Systems, a leading provider of specialized clinical laboratory and anatomic pathology testing services and disease management systems focusing on cancer, pre-natal genetics and cytogenetics.  Dianon Systems was sold to LabCorp in 2002.  In addition, he served as President and CEO of Calypte Biomedical, a biodiagnostics company that developed the first urine-based HIV test, where he shepherded the company through its IPO.  Previously, he was Division Vice President and worldwide General Manager of Abbott Laboratories Diagnostics Products business unit.

HistoRx CEO Rana K. Gupta approached Mr. Davis with the opportunity, commenting, "Now that HistoRx has proven our license model for diagnostics commercialization, it's crucial to expand our expertise in both the laboratory services business and the diagnostic product arena since these are the avenues of distribution we will continue to pursue.  Jack's experience with running Abbott's worldwide Diagnostics Products business and with building a national anatomic pathology services business at Dianon make him a valuable addition to the HistoRx Board."

"I'm delighted to join the board of directors of HistoRx, a company that, working with the Pathology community at large, is committed to improving the objectivity, reproducibility and quantitation of anatomic pathology," Davis stated. "Testing services based on AQUA technology are improving the quality of care in cancer diagnostics."

About HistoRx (www.historx.com)

HistoRx, Inc. is a leading developer of tissue-based theranostic solutions to advance individualized patient care.  The Company's products and services are based on proprietary AQUA® technology for tissue biomarker analysis.  AQUA® software is the only platform capable of precisely measuring protein biomarker concentration with sub-cellular resolution in tissue sections, enabling fully objective, standardized, reproducible, and automated analysis to guide targeted drug development and therapeutic decision making.  HistoRx currently helps biopharmaceutical companies advance their product pipelines by generating valuable new insights into the safety and effectiveness of targeted therapeutics in development for cancer and other diseases, and is developing clinical assays based on these insights.  For more information please visit www.historx.com.


'/>"/>
SOURCE HistoRx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Ridge Diagnostics, Inc. Presents Clinical Data on Blood Test for Depression at U.S. Psychiatric and Mental Health Congress
2. The Future of Molecular Diagnostics: Innovative Technologies Driving Market Opportunities in Personalized Medicine
3. bioMerieux and Biocartis Sign Strategic Partnership in Molecular Diagnostics
4. Quest Diagnostics Increases Share Repurchase Authority By $250 Million
5. Signal Genetics Announces Partnership with Array BioPharma to Advance a Multiple Myeloma Program Backed by Companion Diagnostics
6. Reportlinker Adds China In Vitro Diagnostics Market Outlook to 2016
7. Reportlinker Adds Molecular Diagnostics Market: DNA Probes and Biochips -- New Product Development Opportunities and Business Expansion Strategies for Instrument and Reagent Suppliers
8. QIAGEN and Roche Settle Dispute Over Distribution Agreement for TheraScreen Companion Diagnostics
9. Abviva Announces Further Patent Issuance for Technology Used in Breast Cancer Diagnostics and Therapeutics
10. BIO 2010: German Molecular Diagnostics Segment Posting Double-Digit Growth
11. Life Sciences Company Sword Diagnostics Moves Operations to Chicago
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... MANASSAS, Va. , Feb. 5, 2016 ... organization, is poised to assist the medical and life ... concerns around Zika Virus infection.   CDC ... --> Zika virus is a single-stranded ... also includes the West Nile, Dengue and Chikungunya Viruses. ...
(Date:2/5/2016)... -- Amarantus BioScience Holdings, Inc. ... products for Regenerative Medicine, Neurology and Orphan Diseases, announced ... from the US Food and Drug Administration (FDA) for ... granted orphan drug designation (ODD) by the US FDA ... Inc. (OTCQB: AMBS), a biotechnology company ...
(Date:2/4/2016)... -- - New FDA action date of July ... date of July 22, 2016   --> ... 2016   - Lifitegrast has the potential ... the treatment of signs and symptoms of dry eye disease in ... be the only product approved in the U.S. in the past decade indicated for the ...
(Date:2/4/2016)... ... February 04, 2016 , ... ... Forensics Club, takes place February 5-6 at the University’s student center, Kehr ... activities such as workshops and competitions for ample networking, learning and collaborating ...
Breaking Biology Technology:
(Date:1/15/2016)... 15, 2016 Recent publicized breaches in cyber ... new ways to ensure data security and user authentication ... and Android that ties a user,s mobile ... into a hardware authorization token. Customer service agents who ... on their KodeKey enabled device to verify their identity. ...
(Date:1/11/2016)... , Jan. 11, 2016  higi, the ... nearly 10,000 retail locations, web and mobile, today ... $40 million from existing investors. ... be devoted to further innovate higi,s health platform ... and web portal – including expanding services and ...
(Date:1/7/2016)... LONDON , Jan. 7, 2016 ... demand for biopharmaceutical products such as biologics and ... pressure to reduce healthcare expenditure, growing demand for ... growing aging population. Biosimilars are similar versions of ... with regards to their quality, safety, and efficacy. ...
Breaking Biology News(10 mins):